A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia

American Journal of Hematology

Volumn 87, Issue 10, 2012, Pages 961-968

  Huh, Jungwon ^a   Kim, Hee Je ^b   Jung, Chul Won ^c   Kim, Hee Jin ^c   Kim, Sun Hee ^c   Kim, Yeo Kyeoung ^d   Kim, Hyeoung Joon ^d   Shin, Myung Geun ^d   Moon, Joon Ho ^e   Sohn, Sang Kyun ^e   Kim, Sung Hyun ^f   Lee, Won Sik ^g   Won, Jong Ho ^h   Mun, Yeung Chul ^a   Kim, Hawk ⁱ   Park, Jinny ^j   Min, Woo Sung ^b   Kim, Dong Hwan ^c,k  

^a Ewha Womans University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^e Kyungpook National University Hospital   (South Korea)

^f Dong A University   (South Korea)

^g Inje University College of Medicine   (South Korea)

^h Soonchunhyang University   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j Gachon University   (South Korea)

^k UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; METAPHASE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME INVERSION; CORE BINDING FACTORS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IDARUBICIN; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-KIT; REMISSION INDUCTION; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84866752027     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23281     Document Type: Article

References (35)

1. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
4. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041-1044.
5. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80: 1825-1831.
6. Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol 2004; 22: 1087-1094.
7. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17: 3767-3775.
8. Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705-5717.
9. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741-3750.
10. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006; 20: 965-970.
11. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003; 121: 775-777.
12. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 2006; 107: 3463-3468.
13. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904-3911.
14. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006; 107: 1791-1799.
15. Shimada A, Taki T, Tabuchi K, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group. Blood 2006; 107: 1806-1809.
16. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006; 135: 165-173.
17. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
18. Maciejewski JP, Tiu RV, O'Keefe C. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol 2009; 146: 479-488.
19. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008; 112: 965-974.
20. Dutt A, Beroukhim R. Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol 2007; 19: 43-49.
21. Mao X, Young BD, Lu YJ. The application of single nucleotide polymorphism microarrays in cancer research. Curr Genomics 2007; 8: 219-228.
22. Tiu RV, Gondek LP, O'Keefe CL, et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009; 27: 5219-5226.
23. Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117: 4552-4560.
24. Park HS, Kim DW, Kim CC, et al. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: A newly designed induction regimen-A prospective, cooperative multicenter study. Semin Hematol 1996; 33: 24-29.
25. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Basel: Karger; 2009.
26. Cheson BD. Overview of the revised response criteria for acute myelogenous leukemia. Clin Adv Hematol Oncol 2004; 2: 277-279.
27. Akagi T, Shih LY, Ogawa S, et al. Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells. Haematologica 2009; 94: 1301-1306.
28. Kühn MW, Radtke I, Bullinger L, et al. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood 2012; 119: e67-e75.
29. Rocquain J, Gelsi-Boyer V, Adélaïde J, et al. Alteration of cohesin genes in myeloid diseases. Am J Hematol 2010; 85: 717-719.
30. Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012; 51: 743-755.
31. Score J, Hidalgo-Curtis C, Jones AV, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012; 119: 1208-1213.
32. Yi JH, Huh J, Kim HJ, et al. Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype. J Clin Oncol 2011; 29: 4702-4708.
33. Makishima H, Maciejewski JP. Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res 2011; 17: 3913-3923.
34. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med 2009; 15: 120-128.
35. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.